In vitro cytotoxicity of docetaxel in childhood acute leukemias

Journal of Clinical Oncology

Volumn 16, Issue 3, 1998, Pages 907-913

  Consolini, Rita ^a   Pui, Ching Hon ^a   Behm, Frederick G ^a   Raimondi, Susana C ^a   Campana, Dario ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; PACLITAXEL; TAXOID; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ALLOGENIC BONE MARROW TRANSPLANTATION; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CHILD; CHILDHOOD LEUKEMIA; CHROMOSOME 11Q; CLINICAL ARTICLE; CYTOTOXICITY; DOSE RESPONSE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; INFANT; KARYOTYPE; LEUKEMIA CELL; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL;

EID: 0031911487     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.3.907     Document Type: Article

References (49)

1. Pui C-H: Childhood leukemias. N Engl J Med 332:1618-1623, 1995
2. Riou JF, Naudin A, Lavelle F: Effects of taxotere on murine and human tumor cell lines. Biochem Biophys Res Commun 187:164-170, 1992
3. Hill BT, Whelan RDH, Shellard SA, et al: Differential cytotoxic effects of docetaxel in a range of mammalian tumor cell lines and certain drug resistant sublines in vitro. Invest New Drugs 12:169-182, 1994
4. Bissery MC: Preclinical pharmacology of docetaxel. Eur J Cancer 31A:S1-S6, 1995 (suppl 4)
5. Verweij J, Clavel M, Chevalier B: Paclitaxel (Taxol) and docetaxel (Taxotere): Not simply two of a kind. Ann Oncol 5:495-505, 1994
6. Wani MC, Taylor HL, Wall ME, et al: Plant antitumor agents. VI. The isolation and structure of Taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J Am Chem Soc 93:2325-2327, 1971
7. Mangatal L, Adeline MT, Guenard D, et al: Application of the vicinal oxyamination reaction with asymmetric induction to the hemisynthesis of Taxol and analogues. Tetrahedron 45:4177-4190, 1989
8. Schiff PB, Fant J, Horwitz SB: Promotion of microtubule assembly in vitro by Taxol. Nature 277:665-667, 1979
9. Lavelle F, Bissery MC, Combeau C, et al: Preclinical evaluation of docetaxel (Taxotere). Semin Oncol 22:3-16, 1995
10. Pronk LC, Stoter G, Verweij J: Docetaxel (Taxotere): Single agent activity, development of combination treatment and reducing side-effects. Cancer Treat Rev 21:463-478, 1995
11. Cortes JE, Pazdur R: Docetaxel. J Clin Oncol 13:2643-2655, 1995
12. Eisenhauer EA: Docetaxel: Current status and future prospects. J Clin Oncol 13:2865-2868, 1995
13. Riccardi A, Servidei T, Tornesello A, et al: Cytotoxicity of paclitaxel and docetaxel in human neuroblastoma cell lines. Eur J Cancer 31A:494-499, 1995
14. Braakhuis BJM, Hill BT, Dietel M, et al: In vitro antiproliferative activity of docetaxel (Taxotere), paclitaxel (Taxol) and cisplatin against human tumour and normal bone marrow cells. Anticancer Res 14:205-208, 1994
15. Vogel M, Hilsenbeck SG, Depenbrock H, et al: Preclinical activity of taxotere (RP 56976, NSC 628503) against freshly explanted clonogenic human tumour cells: Comparison with Taxol and conventional antineoplastic drugs. Br J Cancer 29A:2009-2014, 1993
16. Nicoletti MI, Lucchini V, D'Incalci M, et al: Comparison of paclitaxel and docetaxel activity on human ovarian carcinoma xenografts. Eur J Cancer 30A:691-696, 1994
17. Hanauske AR, Degen D, Hilsenbeck SG, et al: Effects of Taxotere and Taxol on in vitro colony formation of freshly explanted human tumour cells. Anticancer Drugs 3:121-124, 1992
18. Bissery MC, Guenard D, Gueritte-Voegelein F, et al: Experimental antitumor activity of taxotere (RP 56976, NSC 628503), a Taxol analogue. Cancer Res 51:4845-4852, 1991
19. Boven E, Venema-Gaberscek E, Erkelens CAM, et al: Antitumor activity of Taxotere (RP 56976, NSC 628503), a new Taxol analog, in experimental ovarian cancer. Ann Oncol 4:321-324, 1993
20. Braakhuis BJM, Kegel A, Welters MJP: The growth inhibiting effect of docetaxel (Taxotere) in head and neck squamous cell carcinoma xenografts. Cancer Lett 81:151-154, 1994
21. Manabe A, Coustan-Smith E, Behm FG, et al: Bone marrow derived stromal cells prevent apoptotic cell death in B lineage acute lymphoblastic leukemia. Blood 79:2370-2377, 1992
22. Campana D, Manabe A, Evans WE: Stroma-supportcd immunocytometric assay (SIA): A novel method for testing the sensitivity of acute lymphoblastic leukemia cells to cytotoxic drugs. Leukemia 7:482-488, 1993
23. Manabe A, Yi T, Kumagai M, et al: Use of stroma-supported cultures of leukemic cells to assess antileukemic drugs. I. Cytotoxicity of interferon alpha in acute lymphoblastic leukemia. Leukemia 7:1900-1905, 1993
24. Manabe A, Coustan-Smith E, Kumagai M, et al: Interleukin-4 induces programmed cell death (apoptosis) in cases of high risk acute lymphoblastic leukemia. Blood 83:1731-1737, 1994
25. Kumagai M, Manabe A, Coustan-Smith E, et al: Use of stroma-supported cultures of leukemic cells to assess antileukemic drugs. II. Potent cytotoxicity of 2-chloro-deoxyadenosine in acute lymphoblastic leukemia. Leukemia 8:1116-1123, 1994
26. Kumagai M, Coustan-Smith E, Murry DJ, et al: Ligation of CD38 suppresses human B lymphopoiesis. J Exp Med 181:1101-1110, 1995
27. Kumagai M, Manabe A, Pui C-H, et al: Stroma-supported culture of childhood B-lineage acute lymphoblastic leukemia cells on bone marrow stroma predicts treatment outcome. J Clin Invest 97:755-760, 1996
28. Ito C, Evans WE, McNinch L, et al: Comparative cytotoxicity of dexamethasone and prednisolone in childhood acute lymphoblastic leukemia. J Clin Oncol 14:2370-2376, 1996
29. Nishigaki H, Ito C, Manabe A, et al: Prevalence and growth characteristics of malignant stem cells in B-lineage acute lymphoblastic leukemia. Blood 89:3735-3744, 1997
30. Martin SJ, Reutelingsperger CPM, McGahon AJ, et al: Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: Inhibition by overexpression of Bcl-2 and Abl. J Exp Med 182:1597-1604, 1995
31. Bissett D, Setonoians A, Cassidy J, et al: Phase I and pharmacokinetic study of Taxotere (RP 56976) administered as a 24-hour infusion. Cancer Res 53:523-527, 1993
32. Extra JM, Rousseau F, Bruno R, et al: Phase I and pharmacokinetic study of Taxotere (RP 56976; NSC 628503) given as a short intravenous infusion. Cancer Res 53:1037-1042, 1993
33. Darzynkiewicz Z, Juan G, Li X, et al: Cytometry in cell necrobiology: Analysis of apoptosis and accidental cell death (necrosis). Cytometry 27:1-20, 1997
34. Johnson IS, Armstrong JG, Gorman M, et al: The vinca alkaloids: A new class of oncolytic agents. Cancer Res 23:1390-1427, 1963
35. Bhalla K, Ibrado AM, Tourkina E, et al: Taxol induces internucleosomal DNA fragmentation associated with programmed cell death in human myeloid leukemia cells. Leukemia 7:563-568, 1993
36. Ringel I, Horwitz SB: Studies with RP 56976 (Taxotere): A semi-synthetic analog of Taxol. J Natl Cancer Inst 83:288-291, 1991
37. Gueritte-Voegelein F, Guenard D, Lavelle F, et al: Relationships between the structure of Taxol analogues and their antimitotic activity. J Med Chem 34:992-998, 1991
38. Bissery MC, Vrignaud P, Lavelle F: Preclinical profile of docetaxel (Taxotere): Efficacy as a single agent and in combination. Semin Oncol 22:3-16, 1995 (suppl 13)
39. Burns HA, Fields S, Peacock N: Docetaxel (Taxotere) in combination: A step forward. Semin Oncol 6:35-40, 1995 (suppl 130)
40. Ravdin PM, Burris HA III, Cook G, et al: Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer. J Clin Oncol 13:2879-2885, 1993
41. Eisenhauer EA, Trudeau M: An overview of phase II studies of docetaxel in patients with metastatic breast cancer. Eur J Cancer 31A:S11-S13, 1995 (suppl 4)
42. Catimel G, Verweij J, Mattijssen V, et al: Docetaxel (Taxotere): An active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck. EORTC Early Clinical Trials Group. Ann Oncol 5:533-537, 1994
43. Van Hoesel QG, Verweij J, Catimel G, et al: Phase II study with docetaxel (Taxotere) in advanced soft tissue sarcomas of the adult. EORTC Soft Tissue and Bone Sarcoma Group. Ann Oncol 5:539-542, 1994
44. Cerny T, Kaplan S, Pavlidis N, et al: Docetaxel (Taxotere) is active in non-small-cell lung cancer: A phase II trial of the EORTC early clinical trials group (ECTG). Br J Cancer 70:384-387, 1994
45. Francis PA, Rigas JR, Kris MG, et al: Phase II trial of docetaxel in patients with stage III and IV non - small-cell lung cancer. J Clin Oncol 12:1232-1237, 1994
46. Fossella FV, Lee JS, Shin DM, et al: Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small-cell lung cancer. J Clin Oncol 13:645-651, 1995
47. Sulkes A, Smyth J, Sessa C, et al: Docetaxel (Taxotere) in advanced gastric cancer: Results of a phase II clinical trial. Br J Cancer 70:380-383, 1994
48. Francis P, Schneider J, Hann L, et al: Phase II trial of docetaxel in patients with platinum-refractory advanced ovarian cancer. J Clin Oncol 12:2301-2308, 1994
49. Blaney SM, Seibel NL, O'Brien M, et al: Phase I trial of docetaxel administered as a 1-hour infusion in children with refractory solid tumors: A collaborative Pediatric Branch, National Cancer Institute and Children's Cancer Group trial. J Clin Oncol 15:1538-1543, 1997